GoAI
Get started
Alphatec Holdings, Inc. logo

Alphatec Holdings, Inc.

ATEC

NASDAQHealthcareMedical - Devices

Open in GoAI

Regular session

$9.52

+$0.04 · +0.42%

Aug 24, 11:16 AM ET

ATEC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

91

Deep Value

Momentum

33

Weakening

Sentiment

71

Bullish

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Alphatec Holdings, Inc. is a medical technology firm dedicated to engineering and advancing solutions for the surgical management of spinal conditions. Its product array includes the Alpha InformatiX platform, notably the SafeOp Neural InformatiX System, which is engineered to reduce the likelihood of nerve injury during surgery. For access and positioning, Alphatec offers systems such as the Sigma transforaminal lumbar interbody fusion pedicle-based access system, the Sigma PTP Access and Patient Positioning System, and the Squadron lateral retractor, all designed to optimize surgical outcomes. The company's robust line of spinal fixation devices features the Invictus Spinal Fixation System, capable of addressing various thoracolumbar pathologies, alongside its minimally invasive SingleStep System and adaptable Modular Fixation Systems, which enhance screw modularity. Further fixation options include the OsseoScrew system for spinal column restoration and the comprehensive Arsenal spinal fixation platform, catering to a spectrum of degenerative to deformity procedures. Alphatec also provides anterior lumbar plating solutions like the Aspida Anterior Lumbar Plating System for interbody fusion and the AMP Anti-Migration Plate, in addition to cervical fixation options such as the OCT Spinal Fixation System, the Trestle Luxe Anterior Cervical Plate System, and the Insignia Anterior Cervical Plate System. Its portfolio extends to interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Implants. A comprehensive suite of biologics is also available, featuring Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier. The company additionally offers EOS imaging products. Alphatec Holdings markets its diverse product range throughout the United States via a network of independent distributors and its own direct sales force. Established in 1990, the company's headquarters are located in Carlsbad, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Patrick S. Miles
Listed since
Jun 1, 2006
Employees
913

Market position

Day range

Current $9.52

52-week range

Current $9.52

Open
$9.55
Previous close
$9.48
Volume
255.78K
0.08× average
Average volume
3.13M
Average daily volume
Market cap
1.47B USD
Beta
0.86
Market reference 1
50-day average
$9.0922
+4.71% above average
200-day average
$13.0848
-27.24% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.62B USD
EV / EBITDA
-91.1×
Earnings yield
-4.54%
Free cash flow yield
0.09%

Profitability & efficiency

Return on equity
-397.90%
Return on assets
-18.12%
Return on invested capital
-12.77%

Financial health

Current ratio
2.06×
Altman Z-score
-0.47
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends82%31%-20%-72%Gross margin, FY2021: 64.87%Gross margin, FY2022: 66.42%Gross margin, FY2023: 64.32%Gross margin, FY2024: 69.37%Gross margin, FY2025: 69.60%Operating margin, FY2021: -52.65%Operating margin, FY2022: -41.89%Operating margin, FY2023: -35.95%Operating margin, FY2024: -22.27%Operating margin, FY2025: -10.75%Net margin, FY2021: -58.81%Net margin, FY2022: -43.12%Net margin, FY2023: -38.70%Net margin, FY2024: -26.51%Net margin, FY2025: -18.76%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 64.87%. Gross margin FY2022 66.42%. Gross margin FY2023 64.32%. Gross margin FY2024 69.37%. Gross margin FY2025 69.60%. Operating margin FY2021 -52.65%. Operating margin FY2022 -41.89%. Operating margin FY2023 -35.95%. Operating margin FY2024 -22.27%. Operating margin FY2025 -10.75%. Net margin FY2021 -58.81%. Net margin FY2022 -43.12%. Net margin FY2023 -38.70%. Net margin FY2024 -26.51%. Net margin FY2025 -18.76%.

Income trends

Revenue

764.16M USD+24.95%

Operating income

−82.13M USD+39.69%

Net income

−143.36M USD+11.57%
Income trends across reported periods859.23M USD478.92M USD98.6M USD−281.72M USDRevenue, FY2021: 243.21M USDRevenue, FY2022: 350.87M USDRevenue, FY2023: 482.26M USDRevenue, FY2024: 611.56M USDRevenue, FY2025: 764.16M USDOperating income, FY2021: −128.06M USDOperating income, FY2022: −146.98M USDOperating income, FY2023: −173.4M USDOperating income, FY2024: −136.17M USDOperating income, FY2025: −82.13M USDNet income, FY2021: −143.03M USDNet income, FY2022: −151.29M USDNet income, FY2023: −186.64M USDNet income, FY2024: −162.12M USDNet income, FY2025: −143.36M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 243.21M USD. Revenue FY2022 350.87M USD. Revenue FY2023 482.26M USD. Revenue FY2024 611.56M USD. Revenue FY2025 764.16M USD. Operating income FY2021 −128.06M USD. Operating income FY2022 −146.98M USD. Operating income FY2023 −173.4M USD. Operating income FY2024 −136.17M USD. Operating income FY2025 −82.13M USD. Net income FY2021 −143.03M USD. Net income FY2022 −151.29M USD. Net income FY2023 −186.64M USD. Net income FY2024 −162.12M USD. Net income FY2025 −143.36M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue764.16M USD611.56M USD482.26M USD350.87M USD243.21M USD
Cost of goods sold232.27M USD187.3M USD172.06M USD117.81M USD85.45M USD
Gross profit531.89M USD424.26M USD310.2M USD233.06M USD157.76M USD
Research and development76.27M USD80.72M USD70.12M USD44.03M USD32.02M USD
Selling, general, and administrative498.53M USD450.2M USD374.08M USD300.01M USD229.27M USD
Operating expenses614.02M USD560.43M USD483.6M USD380.03M USD285.82M USD
Interest expense21.14M USD24.88M USD16.64M USD5.51M USD7.11M USD
Depreciation and amortization82.56M USD83.32M USD59.68M USD43.93M USD30.17M USD
Operating income−82.13M USD−136.17M USD−173.4M USD−146.98M USD−128.06M USD
Net income−143.36M USD−162.12M USD−186.64M USD−151.29M USD−143.03M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-172.90%
11 comparable reports
Latest EPS result
0.07
Estimate 0.07 · Beat by 0.78%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.150.01-0.13-0.27Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual -0.23, estimate -0.19, surprise -21.05%, Miss. Q2 2025, reported May 1, 2025: actual -0.23, estimate -0.12, surprise -91.67%, Miss. Q3 2025, reported Jul 31, 2025: actual 0.02, estimate -0.06, surprise +133.33%, Beat. Q4 2025, reported Oct 30, 2025: actual 0.03, estimate -0.03, surprise +200.00%, Beat. Q1 2026, reported Feb 24, 2026: actual 0.06, estimate 0.04, surprise +50.00%, Beat. Q2 2026, reported May 5, 2026: actual -0.22, estimate -0.01, surprise -2100.00%, Miss. Q3 2026, reported Aug 4, 2026: actual 0.07, estimate 0.069, surprise +0.78%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 0.11, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates234.45M209.36M184.26M159.16MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 177M USD, estimate 172.76M USD, surprise +2.46%, Beat. Q2 2025, reported May 1, 2025: actual 169.18M USD, estimate 168.18M USD, surprise +0.59%, Beat. Q3 2025, reported Jul 31, 2025: actual 185.54M USD, estimate 178.78M USD, surprise +3.78%, Beat. Q4 2025, reported Oct 30, 2025: actual 196.5M USD, estimate 182.62M USD, surprise +7.60%, Beat. Q1 2026, reported Feb 24, 2026: actual 212.93M USD, estimate 211.54M USD, surprise +0.66%, Beat. Q2 2026, reported May 5, 2026: actual 192.11M USD, estimate 197.51M USD, surprise -2.74%, Miss. Q3 2026, reported Aug 4, 2026: actual 213.51M USD, estimate 211.26M USD, surprise +1.07%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 225.44M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$16.22

70.09% upside
Past 12 months12-month forecastHigh $24.00Average $16.22Low $12.00

ATEC news

defenseworld.net

Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Average Recommendation of “Moderate Buy” from Brokerages

Alphatec Holdings, Inc. (NASDAQ: ATEC - Get Free Report) has been given an average rating of "Moderate Buy" by the fifteen brokerages that are currently covering the stock, MarketBeat Ratings reports. One investment…

Read source
seekingalpha.com

Alphatec Holdings, Inc. (ATEC) Q2 2026 Earnings Call Transcript

Alphatec Holdings, Inc. (ATEC) Q2 2026 Earnings Call Transcript

Read source
zacks.com

Alphatec (ATEC) Q2 Earnings Lag Estimates

Alphatec (ATEC) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.02 per share a year ago.

Read source
marketbeat.com

Alphatec Q2 Earnings Call Highlights

Alphatec NASDAQ: ATEC reported second-quarter 2026 revenue of $214 million, up 15% from a year earlier, as growth in surgical procedures and surgeon adoption supported higher profitability and positive free cash flow.

Read source
businesswire.com

ATEC Reports Second Quarter Financial Results

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a spine-focused provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results…

Read source
businesswire.com

ATEC Announces Participation in Upcoming Investor Conferences

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate…

Read source

ATEC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

ETFs holding ATEC

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
34.75M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.16-0.29%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
29.92M
Weight
0.04%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.58-0.46%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
12.96M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.82-0.70%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
10.84M
Weight
0.07%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$383.92-0.89%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
8.28M
Weight
0.13%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.71-0.48%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
6.63M
Weight
0.04%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.71-0.45%
iShares U.S. Medical Devices ETF logoiShares U.S. Medical Devices ETFIHI
Market value
5.36M
Weight
0.15%
AUM
3.49B USD
Expense ratio
0.37%
Price / 1D
$56.06-0.20%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
5.29M
Weight
0.02%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.465-1.06%

Continue in GoAI

Research ATEC

research.disclaimer